University of California

Five Prime Therapeutics, Inc.

Chiron Corporation

Cor Therapeutics, Inc.

Nuvelo, Inc.

Walking Fish Therapeutics

Other

Washington University

Novartis Vaccines & Diagnostics, Gmbh

Lewis T Williams

Jaime A Escobedo

Kevin Hestir

Ernestine A Lee

Stephen Kohl Doberstein

Elizabeth Bosch

Ge Wu

Hongbing Zhang

David Pot

Diane Hollenbaugh

Justin Wong

Minmin Qin

Ali Sadra

Pauline E Lee

Justin G P Wong

David Lawrence Wolf

Christoph Reinhard

Shannon Marshall

Neill A Giese

Haishan Lin

Larry J Fretto

Pablo Dominguez Garcia

Altaf Kassam

Philip W Majerus

Anne Bennett Jefferson

Srinivas Kothakota

William Michael Kavanaugh

James E Tomlinson

Anke Klippel

Radoje Drmanac

Giulia C Kennedy

Snezana Drmanac

Michael A Innis

Klaus Giese

David B Kita

W Michael Kavanaugh

Stephen David Harrison

Thomas Brennan

Hangil Park

Filippo M Randazzo

Keting Chu

Vivien W Chan

Cindy Leo

Ivan Labat

Aileen Zhou

George Lamson

Julie Sudduth-Klinger

Yen-Wen Chen

Kaoru Morishita

Birgit Stache-Crain

Daniel E Johnson

Yan Wang

Daniel F Johnson

David A Pot

Lisa Molz

Michael Dee Gunn

Amy L Tsui Collins

Michael Rohan

Radomir Crkvenjakov

Mark Dickson

Dirk Behrens

Dena Leshkowitz

Veronica Garcia

Robert Forgan Halenbeck

Lee William Jones

Min Mei Huang

Thomas Linnemann

Robert F Halenbeck

Jeffrey T Finer

Todd W Seeley

Kalyani Penta

Hui Cen

Stephen F Hardy

Dong Wei

Tian-Qiang Sun

Licen Xu

Tasha Marenbach

Loriane Masuoka

Jason G Cyster

J Kevin Ramer

Susan Demo

Kathleen Boyle

Mark Selby

Minmei Huang

Bin Wu

Justin G Wong

Steven Doberstein

Thomas Five Prime Therapeutics Inc Linnemann

The present invention relates to genetically modified B cells and their uses thereof, for example, for the treatment of a variety of diseases and disorders, including cancer, heart disease, inflammatory disease, muscle wasting disease, neurological disease, and the like. In certain embodiments, the invention relates to an isolated modified B cell ('CAR-B cell'), capable of expressing a chimeric receptor (“CAR-B receptor”), wherein said chimeric receptor comprises (a) an extracellular domain; (b) a transmembrane domain; and (c) a cytoplasmic domain that comprises at least one signaling domain. In various embodiments, the invention comprises an isolated modified B cell, wherein said B cell is capable of expressing and secreting a payload, wherein the payload is not naturally expressed in a B cell or is expressed at higher levels than is naturally expressed in a B cell. In various embodiments, the payload is an antibody or fragment thereof.

Modified B cells and methods of use thereof

The present invention relates to genetically modified B cells and their uses thereof, for example, for the treatment of a variety of diseases and disorders, including cancer, heart disease, inflammatory disease, muscle wasting disease, neurological disease, and the like. In certain embodiments, the invention relates to an isolated modified B cell ('CAR-B cell), capable of expressing a chimeric receptor (“CAR-B receptor'), wherein said chimeric receptor comprises (a) an extracellular domain; (b) a transmembrane domain; and (c) a cytoplasmic domain that comprises at least one signaling domain. In various embodiments, the invention comprises an isolated modified B cell, wherein said B cell is capable of expressing and secreting a payload, wherein the payload is not naturally expressed in a B cell or is expressed at higher levels than is naturally expressed in a B cell. In various embodiments, the payload is an antibody or fragment thereof.

The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.

Methods of treating disease with FGFR1 fusion proteins

FGFR2 fusion proteins comprising C-terminal deletion mutants of FGFR2-IIIC

Polynucleotides encoding FGFR1-IIIc ECD fusion proteins

Disclosed is a newly identified secreted molecule, identified herein as 'monocyte, granulocyte, and dendritic cell colony stimulating factor' (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.

Compositions and methods of use for MGD-CSF in disease treatment

The invention provides pharmaceutical polypeptide compositions that promote proteoglycan synthesis, and promote the activity of chondrocyte cells, thereby treating arthritis. Methods of providing these compositions to treat arthritis are also provided.

Compositions for treating arthritis comprising HG1023575 polypeptide

Pharmaceutical polypeptide compositions promote the survival of cardiac cells, recruit cardiac cells to the cardiac area, stimulate the differentiation of cardiac cells, stimulate the proliferation of cardiac cells, and promote the activity of cardiac cells, thereby treating cardiac conditions. Methods of providing these compositions to the cardiac area include catheterization and direct injection. In preferred embodiments, the compositions comprise one of more of the following growth factors: EGF, bFGF, cardiotrophin-1, thrombin, PDGF-BB, amphiregulin, epiregulin, HB-EGF, TGFalpha, betacellulin, heregulin alpha, NRG-1-beta1-HRG-beta1, FGF 9.

Compositions comprising FGF-9 and betacellulin and methods for treating cardiac conditions

Disclosed herein is a newly identified SDF-1 splice variant molecule, its polypeptide sequence, and the polynucleotides encoding the polypeptide sequence, and active fragments thereof. Also provided is a procedure for producing such polypeptides by recombinant techniques employing, for example, vectors and host cells. Also disclosed are methods for utilizing such polypeptides and modulators thereof for the treatment of diseases, including cancer, immune diseases, infectious diseases, and ischemic diseases.

Antibodies to stromal cell-derived factor-1 polypeptides

FGFR3-IIIc fusion proteins

Novel soluble Notch receptor ligands and polynucleotides encoding such are disclosed, as well as methods for producing and using these novel nucleotides and polypeptides. These novel polypeptides or agonists or antagonists thereto modulate cellular activity, regulate the growth and division of cell, including stem cells, progenitor and precursor cells, are involved in cell fate decisions, and provide prophylactic or therapeutic benefits for treatment of human diseases. Expression systems are provided that facilitate the production, secretion, and purification of these molecules.

Human soluble notch receptor ligands

Human endogenous retroviruses of the HML-2 family show up-regulated expression in prostate tumors. This finding can be used in prostate cancer screening, diagnosis and therapy.

Endogenous retroviruses up-regulated in prostate cancer

Stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof and methods of use

The invention provides polynucleotides encoding Notch receptor ligands, encoded polypeptides, and antibodies specific to the polypeptides. Also provided are methods and compositions for enhancing or inhibiting angiogenesis as well as modulating immune responses.

Notch receptor ligands and uses thereof

Growing community of inventors

Mill Valley, CA, United States of America

Lewis T Williams